A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Brief Summary
The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.
Intervention / Treatment
3-treatment period design
-
Lamotrigine (DRUG)Tablet
-
BI 409306 (DRUG)Film-coated tablet
-
Placebo (DRUG)Tablet, Film-coated tablet
-
BI 425809 (DRUG)Film-coated tablet
Condition or Disease
- Healthy
Phase
Study Design
| Study type: | INTERVENTIONAL |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 18 Years to 55 Years |
| Enrollment: | 39 (ACTUAL) |
| Funded by: | Industry |
| Allocation: | Randomized |
| Primary Purpose: | Treatment |
MaskingTRIPLE:
|
|
Clinical Trial Dates
| Start date: | Dec 01, 2020 | ACTUAL |
|---|---|---|
| Primary Completion: | Aug 01, 2022 | ACTUAL |
| Completion Date: | Aug 12, 2022 | ACTUAL |
| Study First Posted: | Oct 26, 2020 | ACTUAL |
| Last Updated: | Aug 19, 2022 |
Sponsors / Collaborators
Participant Groups
-
Treatments: T1: Lamotrigine T2: BI 409306 T3: BI 425809 R: Placebo
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
-
No description provided
Eligibility Criteria
| Sex: | Male |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 55 |
| Age Groups: | Adult |
| Healthy Volunteers: | Yes |
Inclusion Criteria:
1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
2. Age of 18 to 55 years (inclusive)
3. BMI of 18.5 to 32 kg/m2 (inclusive)
4. Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation
5. Male subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion:
* Use of adequate contraception, e.g. use of condom (male subjects) plus any of the following methods (female partners): intrauterine device, hormonal contraception (e.g. implants, injectables, combined oral or vaginal contraceptives) that started at least 2 months prior to first drug administration, or barrier method (e.g. diaphragm with spermicide)
* Sexually abstinent
* Vasectomised (vasectomy at least 1 year prior to enrolment)
* Surgically sterilised female partner (including hysterectomy, bilateral tubal occlusion or bilateral oophorectomy)
* Postmenopausal female partner, defined as at least 1 year of spontaneous amenorrhea
Exclusion Criteria:
1. Any finding in the medical examination (including ECG) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. History of diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply
1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
2. Age of 18 to 55 years (inclusive)
3. BMI of 18.5 to 32 kg/m2 (inclusive)
4. Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation
5. Male subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 30 days after trial completion:
* Use of adequate contraception, e.g. use of condom (male subjects) plus any of the following methods (female partners): intrauterine device, hormonal contraception (e.g. implants, injectables, combined oral or vaginal contraceptives) that started at least 2 months prior to first drug administration, or barrier method (e.g. diaphragm with spermicide)
* Sexually abstinent
* Vasectomised (vasectomy at least 1 year prior to enrolment)
* Surgically sterilised female partner (including hysterectomy, bilateral tubal occlusion or bilateral oophorectomy)
* Postmenopausal female partner, defined as at least 1 year of spontaneous amenorrhea
Exclusion Criteria:
1. Any finding in the medical examination (including ECG) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. History of diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply
Primary Outcomes
-
Paired Associate Learning (PAL) Total Errors Adjusted (PALTEA28) on ketamine up to 41 days
Secondary Outcomes
-
Spatial Working Memory (SWM) Between Errors (BE468) on ketamine up to 41 days
-
Rapid Visual Information Processing A' Prime (RVPA) on ketamine up to 41 days
More Details
| NCT Number: | NCT04602221 |
|---|---|
| Other IDs: | 1289-0057 |
| Study URL: | https://clinicaltrials.gov/study/NCT04602221 |
Last updated: Sep 29, 2023